Prevalence and associated factors of premature discontinuation of antiplatelet therapy after ischemic stroke: a nationwide population-based study

Table 4 Factors associated with premature discontinuation of antiplatelets within 12 months compared to continuers

Factors	Univariate logistic regression analysis		Multivariate logistic regression analysis
Factors	Crude OR (95% CI)	p value	Adjusted OR^a(95% CI)	p value
Total
Sex
Male	1 (reference)		1 (reference)
Female	1.12 (0.98–1.27)	0.086	1.03 (0.90–1.17)	0.688
Age
< 70	1 (reference)		1 (reference)
≥ 70	1.16 (1.02–1.32)	0.022	1.15 (1.00–1.31)	0.044
Income
High	1 (reference)		1 (reference)
Middle	1.16 (1.00–1.35)	0.047	1.20 (1.03–1.40)	0.021
Low	1.27 (1.09–1.49)	0.002	1.21 (1.02–1.45)	0.033
Residential area
Urban	1 (reference)		1 (reference)
Rural	1.44 (1.22–1.71)	0.000	1.36 (1.14–1.62)	0.001
Health insurance
Medicare	1 (reference)		1 (reference)
Medical aid	1.32 (1.04–1.67)	0.023	1.18 (0.89–1.55)	0.204
Charlson comorbidity index
< 6	1 (reference)		1 (reference)
≥ 6	1.40 (1.06–1.84)	0.018	1.50 (1.13–1.98)	0.005
Initiated antiplatelets
Dual therapy	1 (reference)		1 (reference)
Clopidogrel	1.41 (1.16–1.73)	0.001	1.41 (1.15–1.72)	0.001
Aspirin	2.67 (2.18–3.27)	0.000	2.66 (2.17–3.25)	0.000
Number of prescribed medications
≥ 4	1 (reference)		1 (reference)
< 4	1.25 (1.06–1.48)	0.008	1.24 (1.05–1.47)	0.013

OR Odds ratio
^a Adjusted for sex, age, income, residential area, type of health insurance, Charlson comorbidity index, type of initiated antiplatelets, and number of prescribed medications

ISSN: 1471-2377